The study provides the strongest evidence to date supporting the potential of proximal pathway inhibitors to enhance clinical outcomes and quality of life for patients with PNH. Proximal pathway ...

Danicopan is being developed to enhance complement C5 inhibitor therapy, like eculizumab and ravulizumab, by selectively inhibiting factor D within the complement system. Among patients with ...

Blood tests revealed the presence of autoantibodies consistent with all 3 conditions. Researchers from China reported the case of a patient with primary biliary cholangitis (PBC), neuromyelitis optica ...

Artificial intelligence may help physicians better predict infant diseases and introduce necessary interventions in a timely manner. Artificial intelligence (AI) is a powerful tool that can be ...

The evidence presented in the review solves a number of issues that have remained unclear until now. A new review article published in the journal Exploration of Immunology hypothesized that bile ...

The PAH group received significantly less fluids within the first 24 hours compared with controls. On the other hand, they were more likely to require vasopressors. A recent study highlights the ...

Factor-H works to alleviate extreme poverty among people with Huntington disease in Venezuela, Colombia, and Peru. Larry Luxner, senior correspondent for Rare Disease Advisor, interviews Ignacio Muñoz ...

Ordering patterns for KIT and TPSAB1 gene testing revealed strategic approaches to patient care for mast cell disorders. Allergists play a crucial role in the diagnosis of mast cell disorders such as ...

The study notes the ongoing need for standardized management guidelines and further research into alternative therapies for IgG4-RD, especially in recurrent cases. In Surgery Case Reports, researchers ...

This past week was like any other for me. I work and take care of my family and fur babies. I love animals and do not have the heart to pretend they do not exist when the strays come around. I leave ...

Participants will receive subcutaneous doses of RLYB212 every 4 weeks from gestational week 16 until delivery. The European Medicines Agency (EMA) and the UK’s Medicines and Healthcare products ...

SGLT2i therapy was significantly associated with lower mortality but the association was no longer statistically significant when potential immortal time bias was considered. Treatment with ...